# Swaminathan Padmanabhan

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 159 papers | 7,452 citations | 66336 42 h-index | 58576 82 g-index |
| 167 all docs | 167 docs citations | 167 times ranked | 9694 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy. Journal of Clinical Oncology, 2012, 30, 631-636. | 1.6 | 571 |
| 2 | Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2010, 28, 1749-1755. | 1.6 | 541 |
| 3 | Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet, The, 2019, 393, 229-240. | 13.7 | 517 |
| 4 | Clinical Efficacy of Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of a Phase II Study. Journal of Clinical Oncology, 2006, 24, 5343-5349. | 1.6 | 400 |
| 5 | Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia. Clinical Cancer Research, 2016, 22, 868-876. | 7.0 | 262 |
| 6 | Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood, 2010, 115, 3796-3800. | 1.4 | 236 |
| 7 | Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. Leukemia, 2014, 28, 2155-2164. | 7.2 | 232 |
| 8 | A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood, 2012, 120, 4324-4333. | 1.4 | 217 |
| 9 | WTAP is a novel oncogenic protein in acute myeloid leukemia. Leukemia, 2014, 28, 1171-1174. | 7.2 | 208 |
| 10 | Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells. Molecular Cancer Therapeutics, 2014, 13, 1142-1154. | 4.1 | 169 |
| 11 | Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood, 2011, 118, 5126-5129. | 1.4 | 152 |
| 12 | Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory WaldenstrÃ¶m Macroglobulinemia. Journal of Clinical Oncology, 2010, 28, 1422-1428. | 1.6 | 150 |
| 13 | Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20<sup>+</sup> Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study. Journal of Clinical Oncology, 2015, 33, 3467-3474. | 1.6 | 149 |
| 14 | Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with WaldenstrÃ¶m Macroglobulinemia. American Journal of Hematology, 2010, 85, 670-674. | 4.1 | 138 |
| 15 | Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. Blood Advances, 2020, 4, 2871-2883. | 5.2 | 134 |
| 16 | A Phase <scp>IB</scp> multicentre doseâ€determination study of <scp>BHQ</scp>880 in combination with antiâ€myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletalâ€related events. British Journal of Haematology, 2014, 167, 366-375. | 2.5 | 130 |
| 17 | BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD. Molecular Cancer Therapeutics, 2014, 13, 2315-2327. | 4.1 | 123 |
| 18 | Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood, 2011, 117, 6450-6458. | 1.4 | 121 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Allogeneic Vaccination With a B7.1 HLA-A Gene-Modified Adenocarcinoma Cell Line in Patients With Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2004, 22, 2800-2807. | 1.6 | 103 |
| 20 | Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma. Blood, 2021, 137, 3272-3276. | 1.4 | 95 |
| 21 | Oligonucleotide aptamer-drug conjugates for targeted therapy of acute myeloid leukemia. Biomaterials, 2015, 67, 42-51. | 11.4 | 91 |
| 22 | Pre-clinical efficacy of combined therapy with novel Î²-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells. Leukemia, 2015, 29, 1267-1278. | 7.2 | 84 |
| 23 | Parsaclisib, a potent and highly selective PI3KÎ´ inhibitor, in patients with relapsed or refractory B-cell malignancies. Blood, 2019, 133, 1742-1752. | 1.4 | 84 |
| 24 | Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. Cancer, 2011, 117, 2127-2135. | 4.1 | 77 |
| 25 | Ganciclovir Inhibits Lymphocyte Proliferation by Impairing DNA Synthesis. Biology of Blood and Marrow Transplantation, 2007, 13, 765-770. | 2.0 | 74 |
| 26 | Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias. Cancer Chemotherapy and Pharmacology, 2013, 72, 897-908. | 2.3 | 73 |
| 27 | High prevalence of early-onset osteopenia/osteoporosis after allogeneic stem cell transplantation and improvement after bisphosphonate therapy. Bone Marrow Transplantation, 2008, 41, 393-398. | 2.4 | 71 |
| 28 | The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib. Journal of Cellular and Molecular Medicine, 2011, 15, 2057-2070. | 3.6 | 70 |
| 29 | Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma. Blood Advances, 2020, 4, 3943-3951. | 5.2 | 69 |
| 30 | Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors. Targeted Oncology, 2009, 4, 99-105. | 3.6 | 68 |
| 31 | Phase I study of MLN8237â€”investigational Aurora A kinase inhibitorâ€”in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia. Investigational New Drugs, 2014, 32, 489-499. | 2.6 | 67 |
| 32 | Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. Blood, 2019, 133, 2765-2775. | 1.4 | 63 |
| 33 | CRP and ferritin in addition to the EASIX score predict CAR-Tâ€“related toxicity. Blood Advances, 2021, 5, 2799-2806. | 5.2 | 57 |
| 34 | Romidepsin for the Treatment of Peripheral T-Cell Lymphoma. Oncologist, 2015, 20, 1084-1091. | 3.7 | 55 |
| 35 | Characteristics and Treatment of Advanced Breast Implantâ€“Associated Anaplastic Large Cell Lymphoma. Plastic and Reconstructive Surgery, 2019, 143, 41S-50S. | 1.4 | 55 |
| 36 | Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (<scp>MCL</scp>) â€•outcomes and mutation profile from venetoclax resistant <scp>MCL</scp> patients. American Journal of Hematology, 2020, 95, 623-629. | 4.1 | 54 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Phase 1/1<scp>B</scp> trial of the heat shock protein 90 inhibitor <scp>NVP</scp>â€<scp>AUY</scp>922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma. Cancer, 2015, 121, 2185-2192. | 4.1 | 51 |
| 38 | Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXOâ€dependent mechanism. International Journal of Cancer, 2012, 131, 2693-2703. | 5.1 | 50 |
| 39 | Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic Tâ€cell lymphoma. Hematological Oncology, 2017, 35, 914-917. | 1.7 | 50 |
| 40 | An improved index for diagnosis and mortality prediction in malignancy-associated hemophagocytic lymphohistiocytosis. Blood, 2022, 139, 1098-1110. | 1.4 | 46 |
| 41 | A unique aptamer-drug conjugate for targeted therapy of multiple myeloma. Leukemia, 2016, 30, 987-991. | 7.2 | 45 |
| 42 | SMARCAD1 Phosphorylation and Ubiquitination Are Required for Resection during DNA Double-Strand Break Repair. IScience, 2018, 2, 123-135. | 4.1 | 44 |
| 43 | Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K Î´/Î³ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma. Cancers, 2020, 12, 2293. | 3.7 | 44 |
| 44 | Protein Kinase C Î²II Plays an Essential Role in Dendritic Cell Differentiation and Autoregulates Its Own Expression. Journal of Biological Chemistry, 2005, 280, 28412-28423. | 3.4 | 43 |
| 45 | Targeting Aurora Kinases in Cancer Treatment. Current Drug Targets, 2011, 12, 2067-2078. | 2.1 | 43 |
| 46 | Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia. Investigational New Drugs, 2012, 30, 1107-1115. | 2.6 | 43 |
| 47 | Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. Blood Advances, 2020, 4, 1038-1050. | 5.2 | 43 |
| 48 | Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias. Blood, 2010, 116, 4591-4599. | 1.4 | 41 |
| 49 | A prospective randomised study of a rotary powered device (OnControl) for bone marrow aspiration and biopsy. Journal of Clinical Pathology, 2011, 64, 809-813. | 2.0 | 41 |
| 50 | Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors. Cancer Chemotherapy and Pharmacology, 2013, 71, 35-41. | 2.3 | 41 |
| 51 | A multicentre, phase <scp>II</scp> trial of ofatumumab monotherapy in relapsed/progressive diffuse large Bâ€cell lymphoma. British Journal of Haematology, 2013, 163, 334-342. | 2.5 | 40 |
| 52 | Complete Local and Abscopal Responses from a Combination of Radiation and Nivolumab in Refractory Hodgkin's Lymphoma. Radiation Research, 2018, 190, 322. | 1.5 | 36 |
| 53 | HEXIM1 induction is mechanistically involved in mediating anti-AML activity of BET protein bromodomain antagonist. Leukemia, 2016, 30, 504-508. | 7.2 | 34 |
| 54 | Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors. ESMO Open, 2020, 5, e000866. | 4.5 | 34 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Safety of CAR T-cell therapy in kidney transplant recipients. Blood, 2021, 137, 2558-2562. | 1.4 | 33 |
| 56 | PD-L1 expression is associated with ALK positivity and STAT3 activation, but not outcome in patients with systemic anaplastic large cell lymphoma. Modern Pathology, 2020, 33, 324-333. | 5.5 | 31 |
| 57 | Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma. Blood Cancer Discovery, 2022, 3, 385-393. | 5.0 | 29 |
| 58 | Induction of CD8 T-cell-Ifn-Î³ response and positive clinical outcome after immunization with gene-modified allogeneic tumor cells in advanced non-small-cell lung carcinoma. Cancer Gene Therapy, 2003, 10, 850-858. | 4.6 | 27 |
| 59 | Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma. Clinical Cancer Research, 2018, 24, 6150-6159. | 7.0 | 27 |
| 60 | Human leukocyte antigen (HLA) DR15 is associated with reduced incidence of acute GVHD in HLA-matched allogeneic transplantation but does not impact chronic GVHD incidence. Blood, 2006, 107, 1970-1973. | 1.4 | 26 |
| 61 | Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma. Bone Marrow Transplantation, 2008, 41, 613-619. | 2.4 | 25 |
| 62 | T-cell lymphoma secondary to checkpoint inhibitor therapy. , 2020, 8, e000104. | | 25 |
| 63 | Epsteinâ€“Barr-virus-positive large B-cell lymphoma associated with breast implants: an analysis of eight patients suggesting a possible pathogenetic relationship. Modern Pathology, 2021, 34, 2154-2167. | 5.5 | 25 |
| 64 | Leukapheresis reduces 4-week mortality in acute myeloid leukemia patients with hyperleukocytosis â€“ a retrospective study from a tertiary center. Leukemia and Lymphoma, 2017, 58, 2110-2117. | 1.3 | 24 |
| 65 | Day 30 SUVmax predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy. Blood Advances, 2022, 6, 2867-2871. | 5.2 | 24 |
| 66 | Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism. Leukemia and Lymphoma, 2006, 47, 2339-2343. | 1.3 | 23 |
| 67 | Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial. Leukemia and Lymphoma, 2009, 50, 1096-1101. | 1.3 | 22 |
| 68 | Ibrutinibâ€“rituximab followed by R-HCVAD as frontline treatment for young patients (â‰¤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. Lancet Oncology, The, 2022, 23, 406-415. | 10.7 | 22 |
| 69 | Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis. Biology of Blood and Marrow Transplantation, 2020, 26, 665-671. | 2.0 | 21 |
| 70 | G6PD deficiency and severity of COVID19 pneumonia and acute respiratory distress syndrome: tip of the iceberg?. Annals of Hematology, 2021, 100, 667-673. | 1.8 | 21 |
| 71 | Targeting PIM kinase activity significantly augments the efficacy of cytarabine. British Journal of Haematology, 2012, 156, 129-132. | 2.5 | 20 |
| 72 | Mammalian target of rapamycin as a target in hematological malignancies. Targeted Oncology, 2011, 6, 53-61. | 3.6 | 18 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | The Transcription Factor Wilms Tumor 1 Confers Resistance in Myeloid Leukemia Cells against the Proapoptotic Therapeutic Agent TRAIL (Tumor Necrosis Factor Î±-related Apoptosis-inducing Ligand) by Regulating the Antiapoptotic Protein Bcl-xL. Journal of Biological Chemistry, 2012, 287, 32875-32880. | 3.4 | 18 |
| 74 | Utility of18fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma. Annals of Oncology, 2015, 26, 774-779. | 1.2 | 17 |
| 75 | Use of PEG-asparaginase in monomorphic epitheliotropic intestinal T-cell lymphoma, a disease with diagnostic and therapeutic challenges. Ecancermedicalscience, 2017, 11, 771. | 1.1 | 17 |
| 76 | Fimepinostat (CUDCâ€907) in patients with relapsed/refractory diffuse large B cell and highâ€grade Bâ€cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses. British Journal of Haematology, 2021, 195, 201-209. | 2.5 | 17 |
| 77 | Safety Study of Salvage Chemotherapy High-Dose Ara-C/Mitoxantrone (HAM) and Type I FLT3-TKI Crenolanib in First Relapsed/Primary Refractory AML. Blood, 2016, 128, 3983-3983. | 1.4 | 17 |
| 78 | Long-term stability of a patient-convenient 1â€‰mg/ml suspension of tacrolimus for accurate maintenance of stable therapeutic levels. Bone Marrow Transplantation, 2006, 37, 781-784. | 2.4 | 15 |
| 79 | Breast Implant-associated Anaplastic Large Cell Lymphoma. Annals of Surgery, 2022, 275, e245-e249. | 4.2 | 15 |
| 80 | Two cases of hepatic zygomycosis in allogeneic stem cell transplant recipients and review of literature. Transplant Infectious Disease, 2007, 9, 148-152. | 1.7 | 13 |
| 81 | Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma. Clinical Cancer Research, 2020, 26, 3546-3556. | 7.0 | 13 |
| 82 | Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Expressing Peripheral T-Cell Lymphomas. Blood, 2021, 138, 133-133. | 1.4 | 13 |
| 83 | Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma. Blood Advances, 2019, 3, 1356-1367. | 5.2 | 12 |
| 84 | A Comparison of Races and Leukemia Subtypes Among Patients in Different Cancer Survivorship Phases. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, S114-S118. | 0.4 | 11 |
| 85 | Breast implant-associated anaplastic large cell lymphoma: clinical follow-up and analysis of sequential pathologic specimens of untreated patients shows persistent or progressive disease. Modern Pathology, 2021, 34, 2148-2153. | 5.5 | 11 |
| 86 | Lenalidomide Is Active in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Carrying Unfavorable Chromosomal Abnormalities.. Blood, 2007, 110, 754-754. | 1.4 | 11 |
| 87 | Dapsone-Induced Methemoglobinemia after Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2006, 12, 241-242. | 2.0 | 10 |
| 88 | Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis. Clinical Cancer Research, 2019, 25, 6781-6787. | 7.0 | 10 |
| 89 | Safety of gemtuzumab ozogamicin as monotherapy or combination therapy in an expanded-access protocol for patients with relapsed or refractory acute myeloid leukemia. Leukemia and Lymphoma, 2020, 61, 1965-1973. | 1.3 | 10 |
| 90 | New paradigm for radiation in multiple myeloma: lower yet effective dose to avoid radiation toxicity. Haematologica, 2020, 105, e355-e357. | 3.5 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Global Ophthalmology Practice Patterns during COVID-19 Pandemic and Lockdown. Ophthalmic Epidemiology, 2022, 29, 233-244. | 1.7 | 10 |
| 92 | Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer. Cancer Chemotherapy and Pharmacology, 2020, 85, 621-626. | 2.3 | 9 |
| 93 | CD8 expression in anaplastic large cell lymphoma correlates with noncommon morphologic variants and T-cell antigen expression suggesting biological differences with CD8-negative anaplastic large cell lymphoma. Human Pathology, 2020, 98, 1-9. | 2.0 | 9 |
| 94 | Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis. Haematologica, 2022, 107, 899-908. | 3.5 | 9 |
| 95 | Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma. ESMO Open, 2021, 6, 100172. | 4.5 | 9 |
| 96 | Assessment of Radiation Doses Delivered to Organs at Risk Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation Therapy. JAMA Network Open, 2020, 3, e2013935. | 5.9 | 8 |
| 97 | Gamma/Delta Phenotype in Primary Cutaneous T-cell Lymphomas and Lymphoid Proliferations. Surgical Pathology Clinics, 2021, 14, 177-194. | 1.7 | 8 |
| 98 | Ibrutinib Plus Rituximab and Venetoclax (IRV) Followed By Risk-Stratified Observation or Short Course R-Hypercvad/MTX in Young Patients with Previously Untreated Mantle Cell Lymphoma - Phase-II Window-2 Clinical Trial. Blood, 2021, 138, 3525-3525. | 1.4 | 8 |
| 99 | CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study. Blood, 2021, 138, 3560-3560. | 1.4 | 8 |
| 100 | Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma: Final Results from a Phase I/II Open Label Multi-Center Study. Blood, 2021, 138, 1365-1365. | 1.4 | 8 |
| 101 | Aggressive relapse of multiple myeloma with intracerebral extension and associated hemorrhage. Leukemia and Lymphoma, 2007, 48, 1228-1230. | 1.3 | 7 |
| 102 | Cryptococcal meningoencephalitis in patients with mantle cell lymphoma on ibrutinib. Ecancermedicalscience, 2018, 12, 836. | 1.1 | 7 |
| 103 | Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e51-e61. | 0.4 | 7 |
| 104 | Comparison of Access to Novel Drugs for Lymphoma and Chronic Lymphocytic Leukemia Between India and the United States. JCO Global Oncology, 2020, 6, 1124-1133. | 1.8 | 7 |
| 105 | MYC expression is associated with older age, common morphology, increased MYC copy number, and poorer prognosis in patients with ALK+ anaplastic large cell lymphoma. Human Pathology, 2021, 108, 22-31. | 2.0 | 6 |
| 106 | Ongoing, first-in-human, phase I dose escalation study of the investigational CD47-blocker TTI-622 in patients with advanced relapsed or refractory lymphoma.. Journal of Clinical Oncology, 2020, 38, 3030-3030. | 1.6 | 6 |
| 107 | High Frequency and Early Onset of Bone Mineral Density Loss Following Allogeneic Stem Cell Transplantation.. Blood, 2005, 106, 2011-2011. | 1.4 | 6 |
| 108 | Autologous stem cell transplantation for large B-cell lymphoma with secondary central nervous system involvement. Blood Advances, 2022, 6, 2267-2274. | 5.2 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Cross Talk between Radiation and Immunotherapy: The Twain Shall Meet. Radiation Research, 2018, 189, 219-224. | 1.5 | 5 |
| 110 | Adoptive cell therapy for acute myeloid leukemia. Leukemia and Lymphoma, 2019, 60, 1370-1380. | 1.3 | 5 |
| 111 | Anaplastic Large Cell Lymphoma of the Breast Arising in a Burn Cicatrix. Aesthetic Surgery Journal, 2020, 40, NP159-NP163. | 1.6 | 5 |
| 112 | Angioimmunoblastic T-cell lymphoma associated with immune checkpoint inhibitor treatment. JAAD Case Reports, 2020, 6, 1264-1267. | 0.8 | 5 |
| 113 | Targeted based therapy in nodal T-cell lymphomas. Leukemia, 2021, 35, 956-967. | 7.2 | 5 |
| 114 | First Clinical Evidence of In Vivo Natural Killer (NK) Cell Modulation in Chronic Lymphocytic Leukemia (CLL) Patients (pts) Treated with Lenalidomide (L).. Blood, 2006, 108, 2109-2109. | 1.4 | 5 |
| 115 | Simultaneous presentation of acute monoblastic leukemia and mantle cell lymphoma: Case report and review of the literature. Leukemia and Lymphoma, 2005, 46, 1813-1818. | 1.3 | 4 |
| 116 | Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL. Leukemia and Lymphoma, 2020, 61, 1380-1387. | 1.3 | 4 |
| 117 | The impact of cell-of-origin, MYC/Bcl-2 dual expression and MYC rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy. Leukemia and Lymphoma, 2021, 62, 1361-1369. | 1.3 | 4 |
| 118 | Characterization of IMiDs (Immunomodulating Agents) Induced â€œFlare Reactionâ€•in Patients with Chronic Lymphocytic Leukemia (CLL) and Correlation with Changes in Serum Cytokine Levels.. Blood, 2005, 106, 5049-5049. | 1.4 | 4 |
| 119 | Small cell/lymphohistiocytic morphology is associated with peripheral blood involvement, CD8 positivity and retained T-cell antigens, but not outcome in adults with ALK+ anaplastic large cell lymphoma. Modern Pathology, 2022, 35, 412-418. | 5.5 | 4 |
| 120 | Outcomes of lenalidomide retreatment with novel triplet regimens in patients with multiple myeloma progressing on lenalidomideâ€based maintenance therapy. British Journal of Haematology, 2021, 193, e23-e26. | 2.5 | 3 |
| 121 | Nine-Year Follow-up of Patients with Relapsed Follicular Lymphoma after Nonmyeloablative Allogeneic Stem Cell Transplant and Autologous Transplant. Clinical Cancer Research, 2021, 27, 5847-5856. | 7.0 | 3 |
| 122 | Phase 1 trial of carfilzomib in relapsed/refractory peripheral T-cell lymphoma. Annals of Hematology, 2022, 101, 335-340. | 1.8 | 3 |
| 123 | HLA-identical sibling stem-cell transplantation in first-remission AML. Blood, 2007, 110, 4619-4619. | 1.4 | 2 |
| 124 | Human leukocyte antigen DR4 is associated with inferior progression-free survival following allogeneic hematopoietic stem cell transplantation for lymphoid malignancies. Leukemia and Lymphoma, 2008, 49, 1494-1500. | 1.3 | 2 |
| 125 | Use of PEG-asparaginase in a case of Hepatosplenic Î³Î´ T-cell lymphoma with long-term remission after stem cell transplantation. Ecancermedicalscience, 2018, 12, 872. | 1.1 | 2 |
| 126 | Triple-hit lymphoma of the cavernous sinus. Canadian Journal of Ophthalmology, 2019, 54, e61-e66. | 0.7 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Acute myeloid leukemia with eosinophilia after cyclinâ€dependent kinases 4/6 inhibitor treatment due to underlying clonal hematopoiesis of indeterminate potential. American Journal of Hematology, 2019, 94, E82-E85. | 4.1 | 2 |
| 128 | SARS-CoV-2 in multiple myeloma: initial observation and management. Leukemia and Lymphoma, 2020, 61, 2763-2766. | 1.3 | 2 |
| 129 | Imaging Surveillance of Limited-stage Classic Hodgkin Lymphoma Patients After PETâ€“CT-documented First Remission. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 533-541. | 0.4 | 2 |
| 130 | Anaplastic lymphoma kinase (ALK)â€negative anaplastic large cell lymphoma with MYC rearrangement. British Journal of Haematology, 2021, 192, e17-e21. | 2.5 | 2 |
| 131 | Final Results of Phase 1/1b Study of Tenalisib, Dual PI3K Î´/Î³ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma. Blood, 2019, 134, 2831-2831. | 1.4 | 2 |
| 132 | Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma Patients in Complete Metabolic Response at Time of Infusion. Blood, 2021, 138, 1740-1740. | 1.4 | 2 |
| 133 | The Echelon-2 Trial: 5-Year Exploratory Subgroup Analyses of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Vs CHOP in Frontline Treatment of Pts with CD30-Positive Peripheral T-Cell Lymphoma. Blood, 2021, 138, 135-135. | 1.4 | 2 |
| 134 | Acute lymphoblastic leukemia presenting with avascular necrosis of the elbow. Leukemia and Lymphoma, 2009, 50, 297-299. | 1.3 | 1 |
| 135 | BCL-W expression associates with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified. Blood Cancer Journal, 2021, 11, 153. | 6.2 | 1 |
| 136 | Aggressive primary cutaneous anaplastic large cell lymphoma with massive bilateral upper limb involvement at relapse. JAAD Case Reports, 2021, 17, 34-37. | 0.8 | 1 |
| 137 | Results From a Phase 1 Multicenter Trial of Alisertib (MLN8237)â€“An Investigational Aurora A Kinase Inhibitorâ€“in Patients with Advanced Hematologic Malignancies. Blood, 2011, 118, 2477-2477. | 1.4 | 1 |
| 138 | Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China. Oncotarget, 2017, 8, 41620-41630. | 1.8 | 1 |
| 139 | Emerging Therapeutic Landscape of Peripheral T-Cell Lymphomas Based on Advances in Biology: Current Status and Future Directions. Cancers, 2021, 13, 5627. | 3.7 | 1 |
| 140 | The Easix (Endothelial Activation and Stress Index) Score Predicts for CAR T Related Toxicity in Patients Receiving Axicabtagene Ciloleucel (axi-cel) for Non-Hodgkin Lymphoma (NHL). Blood, 2020, 136, 17-18. | 1.4 | 1 |
| 141 | Gut Bacterial Diversity Associates with Efficacy of Anti-CD19 CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma. Blood, 2020, 136, 34-35. | 1.4 | 1 |
| 142 | Association of Vitamin D Deficiency with Inferior Treatment Outcomes in Patients with Newly Diagnosed Classic Hodgkin Lymphoma: MD Anderson Cancer Center Experience. Blood, 2020, 136, 27-28. | 1.4 | 1 |
| 143 | Sustained response to erythropoietin for anemia in NK-cell large granular lymphocytosis: a brief case report. Leukemia Research Reports, 2022, 17, 100292. | 0.4 | 1 |
| 144 | The Leukemic Phase of ALK-Negative Anaplastic Large Cell Lymphoma Is Associated with CD7 Positivity, Complex Karyotype, TP53 Deletion, and a Poor Prognosis. Cancers, 2021, 13, 6316. | 3.7 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Unicentric Castleman disease, hyaline vascular variant, stromal rich, with increased plasma cells and a high level of serum IL-6: Raising the diagnostic and therapeutic issues. Annals of Diagnostic Pathology, 2019, 43, 151398. | 1.3 | 0 |
| 146 | Oral Abstract: TCL-150: The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S203. | 0.4 | 0 |
| 147 | Effect of Bone Marrow Hypoplasia Secondary to Reinduction Therapy for Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) on Outcomes after Blood and Marrow Transplantation (BMT).. Blood, 2006, 108, 3033-3033. | 1.4 | 0 |
| 148 | Osteonecrosis of the Jaw (ONJ) in Patients with Multiple Myeloma, Receiving Bisphosphonate Therapy, Is Independent of Renal Function: Single Institute Experience of an Emerging Clinical Problem.. Blood, 2006, 108, 5129-5129. | 1.4 | 0 |
| 149 | An Integer Weighted Genomic Mutation Scoring (IWGMS) Using the Trusight Myeloid Sequencing Panel (Illumina) Shows Higher Mortality in Patients with Intermediate Risk Acute Myeloid Leukemia- a Retrospective Study. Blood, 2016, 128, 2889-2889. | 1.4 | 0 |
| 150 | Demand and Supply of Face Masks during the COVID-19 Pandemic. Smart and Sustainable Manufacturing Systems, 2020, 4, 20200069. | 0.7 | 0 |
| 151 | No Difference in Survival Among Black Patients with Mycosis Fungoides and SÃ©zary Syndrome: A Multicenter Retrospective Analysis. Blood, 2021, 138, 2441-2441. | 1.4 | 0 |
| 152 | Analysis of Factors Associated with Conversion to CR in Patients with Large B-Cell Lymphoma Achieving Day 30 PR after CAR T-Cell Therapy. Blood, 2021, 138, 3870-3870. | 1.4 | 0 |
| 153 | A Risk Score Incorporating Low Pass Whole Genome Sequencing of Cell Free DNA from Patients Receiving CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma. Blood, 2021, 138, 38-38. | 1.4 | 0 |
| 154 | Factors Associated with the Improvement of Outcomes of High-Risk Relapsed Hodgkin Lymphoma (HL) Patients Receiving High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT): The MD Anderson Cancer Center Experience. Blood, 2020, 136, 17-18. | 1.4 | 0 |
| 155 | Nonmyeloablative Allogeneic Stem Cell Transplantation with or without Inotuzumab Ozogamicin for Lymphoid Malignancies. Blood, 2020, 136, 10-12. | 1.4 | 0 |
| 156 | 51â€...Small cell/lymphohistiocytic morphology is associated with CD8 positivity, retained T cell markers, a trend of decreased PD-L1 expression, but not outcome in adults with ALK+ ALCL. , 2020, , . | | 0 |
| 157 | A Novel Inflammatory Index Is Sufficient to Identify Hemophagocytic Lymphohistiocytosis in Adult Patients with Hematologic Malignancies. Blood, 2020, 136, 1-2. | 1.4 | 0 |
| 158 | Autologous Stem Cell Transplantation for Angioimmunoblastic T-Cell Lymphoma. Blood, 2020, 136, 40-41. | 1.4 | 0 |
| 159 | Herpesviruses Infections in CAR T Cell Recipients. Transplantation and Cellular Therapy, 2022, 28, S381-S382. | 1.2 | 0 |